UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026 (Report No. 23)

Commission File Number: 001-42796

Nasus Pharma Ltd.

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

~~Results~~Press ~~of Special General Meeting of Shareholders~~Release

On March 516, 2026, Nasus Pharma Ltd., ~~(the~~issued a press release titled “~~Company”)~~Nasus ~~convened~~Pharma aAnnounces ~~Special~~Positive ~~General~~Top ~~Meeting~~Line Data from Phase 2 Clinical Study of ~~Shareholders~~NS002: ~~(the~~Achieves ~~“Meeting~~Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold,”) a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

AtInvestor the Meeting, a quorum was present and the shareholders of the Company voted upon and approved, by the applicable required majority, all agenda items that were described in the Company’s notice for the Meeting and proxy statement for the Meeting (including amending and restating the Company’s Articles of Association to increase its authorized share capital), which were included as Exhibits 99.1 and 99.2, respectively, to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on January 29, 2026.Presentation

~~Attached~~On ~~hereto~~March as16, ~~Exhibit~~2026, 99the Company made available an updated corporate presentation on its website.1 isA copy of the ~~Company’s~~corporate ~~Amended~~presentation ~~and~~is attached ~~Restated~~hereto ~~Articles~~as Exhibit 99.2 to this Report of ~~Association,~~Foreign asPrivate ~~amended~~Issuer on ~~March~~Form ~~5, 2026~~6-K.

EXHIBIT INDEX

Exhibit No.		Description
99.1		~~Amended~~Press ~~and~~Release ~~Restated~~issued ~~Articles~~on ofMarch ~~Association~~16, of2026, by Nasus Pharma Ltd., astitled ~~amended~~“Nasus onPharma ~~March~~Announces 5,Positive ~~2026~~Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold.”
99.2		Corporate Presentation, dated March 2026.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NASUS PHARMA LTD.
Date: March 6, 2026	By:	/s/ Dan Teleman
Date: March 16, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

Filing Compare · Nasus Pharma Ltd